<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013115</url>
  </required_header>
  <id_info>
    <org_study_id>curosurf/Budesonide for NRDS</org_study_id>
    <nct_id>NCT02013115</nct_id>
  </id_info>
  <brief_title>Curosurf/Budesonide for Infants With Respiratory Distress Syndrome</brief_title>
  <acronym>Budesonide</acronym>
  <official_title>Curosurf/Budesonide for Infants With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome
      usually need the second or more pulmonary surfactant and is easier to developing to
      Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome,
      Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is
      Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of
      Brochopulmonary dysplasia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need of pulmonary surfactant</measure>
    <time_frame>one month</time_frame>
    <description>The hypothesis is Cursurf/Budesonide could reduced the need of pulmonary surfactant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the incidence of bronchopulmonary dysplasia</measure>
    <time_frame>gestional age 36 weeks or later</time_frame>
    <description>the hypothesis is Cursurf and Budesonide could reduced the incidence of bronchopulmonary dysplasia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>need of intubation</measure>
    <time_frame>one month</time_frame>
    <description>The hypothesis is Cursurf/Budesonide could reduced the need of intubation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Cursurf</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The baby with respiratory distress syndrome was given Cursurf through intubation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cursurf and Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation</description>
    <arm_group_label>Cursurf and Budesonide</arm_group_label>
    <other_name>Pumicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of respiratory distress syndrome

        Exclusion Criteria:

          -  pneumothorax

          -  surgical disease

          -  major congenical defects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Chen Long,MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>infant</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

